Prestige Consumer Healthcare (PBH) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's stock. Their PBH share price forecasts range from $71.00 to $104.00. On average, they predict the company's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.

Prestige Consumer Healthcare's stock was trading at $62.60 at the beginning of 2023. Since then, PBH shares have decreased by 7.7% and is now trading at $57.7550.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PBH earnings forecast.

Prestige Consumer Healthcare Inc. (NYSE:PBH) issued its earnings results on Thursday, May, 4th. The company reported $1.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.04 by $0.03. The firm had revenue of $285.90 million for the quarter, compared to analysts' expectations of $280.58 million. Prestige Consumer Healthcare had a positive trailing twelve-month return on equity of 13.38% and a negative net margin of 7.30%. Prestige Consumer Healthcare's revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.91 EPS.

ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), SPDR S&P Pharmaceuticals ETF (XPH), Global X Health & Wellness ETF (BFIT), ETC 6 Meridian Small Cap Equity ETF (SIXS), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $4.27-$4.32 for the period, compared to the consensus EPS estimate of $4.18. The company issued revenue guidance of $1.14 billion-$1.14 billion, compared to the consensus revenue estimate of $1.12 billion.

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.35%), Dimensional Fund Advisors LP (7.40%), Macquarie Group Ltd. (5.54%), State Street Corp (3.85%), FMR LLC (2.14%) and Geode Capital Management LLC (2.07%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBH stock can currently be purchased for approximately $57.76.

Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $2.87 billion and generates $1.13 billion in revenue each year. The company earns $-82,310,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis.

The company employs 505 workers across the globe.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.